FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Non Small Cell Lung Cancer|Colorectal Cancer|Breast Cancer|Ovarian Cancer|Pancreatic Cancer|Head and Neck Cancer|GastroEsophageal Cancer
Interventions: DRUG: FT536|DRUG: Cyclophosphamide|DRUG: Fludarabine|DRUG: IL-2|COMBINATION_PRODUCT: Avelumab|COMBINATION_PRODUCT: Pembrolizumab|COMBINATION_PRODUCT: Nivolumab|COMBINATION_PRODUCT: Atezolizumab|COMBINATION_PRODUCT: Trastuzumab|COMBINATION_PRODUCT: Cetuximab|COMBINATION_PRODUCT: Amivantamab|DRUG: IL-2
Sponsor: Fate Therapeutics